As both a researcher and a person with cystic fibrosis, it is an amazing experience to watch cells with rare CF mutations respond to drugs in the lab. Knowing the scientific basis for my treatments not only gives me a sense of control, but it encourages me to do my treatments.
Site Search
On July 9, the Cystic Fibrosis Foundation's President and CEO, Dr. Michael P. Boyle, participated in the global launch of the AMR Action Fund. Alongside leaders in global health, Dr. Boyle highlighted the critical need of antibiotics for people living with CF and stressed that research investment alone will not solve the challenges of antibiotic development.
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.